Key Highlights

  • enGene (NASDAQ:ENGN) traded at USD 2.16 on November 12, 2026, up 20.05% from an implied prior close of about USD 1.80, on Volume of 6.33 million shares, about 5.6 times normal.
  • The move followed a November 11 update from the pivotal LEGEND trial, in which 56% of 120 evaluable patients achieved a complete response at any time.
  • The company said it will begin a rolling Biologics License Application for detalimogene by the end of 2026, with potential approval in 2027.
  • A brokerage also lifted its rating on the stock to an overweight equivalent on November 12, adding to buying interest during the session.

The Catalyst: Stronger Durability in LEGEND

enGene (NASDAQ:ENGN) develops detalimogene, a non-viral gene therapy delivered directly into the bladder for patients with non-muscle invasive bladder cancer that no longer responds to BCG, the standard immunotherapy. The November 11 update used an October 29, 2026 data cutoff, with 120 of 125 enrolled patients evaluable. The complete response rate at any time rose to 56% from 54% at the previous update. The more important change was durability. The 12-month landmark complete response rate improved to 24% from 13%, the estimated share of responders still in response at 12 months rose to 43% from 25%, and the median duration of response lengthened to 10.1 months from 8.6. Some 97% of evaluable patients remained free of progression to muscle invasive disease, and 86% avoided bladder removal, including 96% of responders. The improvement in durability addresses the main concern investors had raised after earlier readouts.

Filing Plan, Safety and the Rating Change

The company expects to start its rolling submission by year-end, complete it in the first half of 2027 and potentially secure approval in 2027. The safety profile supports that plan. Treatment-related adverse events occurred in 59% of patients, mostly Grade 1 or 2, Grade 3 events affected 4% and serious treatment-related events 2%, with no Grade 4 or 5 events. A non-viral therapy is simpler to manufacture and handle than viral gene therapies and can be given in a urology office, which could help adoption among community practices. On November 12 a brokerage upgraded the shares to an overweight equivalent rating, citing the improved data. The combination of better durability, a defined filing timeline and a supportive rating change explains why buyers stepped in during the session, with relative volume well above the stock's usual level. A mid-2027 update is also planned for a cohort that uses a bladder rinse designed to improve uptake of the therapy.

Fundamentals and Risks

At USD 2.16, enGene (NASDAQ:ENGN) carried a Market Value of about USD 144.82 million on the screen, with trailing diluted losses of USD 2.08 per share and no product revenue. As a clinical-stage company it will need Capital to build a commercial team and launch the product, so dilution risk remains part of the Investment case. The market for BCG-unresponsive disease has become crowded, with several therapies approved or close to approval, and some rivals have reported higher sustained response rates. A 24% complete response at 12 months will be the figure physicians and regulators compare. The trial is single-arm, which is normal in this setting but leaves cross-trial comparisons open to debate. Investors should watch the start of the filing, longer follow-up, any Partnership with a larger oncology company and the company's cash runway disclosures.

Where Things Stand

enGene (NASDAQ:ENGN) rose 20.05% to USD 2.16 on November 12, 2026 after LEGEND data showed a 56% complete response rate and clearly better durability, alongside a plan to begin its BLA by year-end and a rating upgrade. The mild safety profile supports the filing. Funding needs, competition and the 24% 12-month response rate are the key debates as the company moves toward a possible 2027 approval.